Skip to main content
Signal8
Launch Terminal

Vistagen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to advancing and commercializing innovative medications for anxiety, depression, and various other disorders impacting the central nervous system (CNS). A key component of its CNS pipeline is PH94B, a fast-acting neuroactive nasal spray currently in Phase III trials for the rapid treatment of anxiety in adults experiencing social anxiety disorder. PH94B also shows potential for addressing a broader spectrum of anxiety conditions, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder (PTSD), pre-procedural anxiety, and panic disorders. The company's CNS development initiatives further encompass PH10, another quick-acting neuroactive nasal spray, which is in preparation for Phase 2B clinical assessment as a standalone therapy for major depressive disorder (MDD). Additionally, VistaGen is developing AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is being investigated in conjunction with oral probenecid for its potential application in treating levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. VistaGen has established various collaborations, including a contract research and development agreement with Cato Research Ltd., a licensing agreement with Pherin Pharmaceuticals, Inc., and a license and collaboration agreement with EverInsight Therapeutics Inc. Founded in 1998, VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

VistaGen Therapeutics, Inc. logo

VistaGen Therapeutics, Inc.

NASDAQ:VTGNHealthcare
-1.41%$0.1683
AH$0.1695+0.71%vs close
Mkt Cap$7.47M
Float44.21M
O/S44.38M
Vol
$ Vol
RVOL
Inst Own26.5%
SI5.6%
Earnings
Dilution
VistaGen Therapeutics, Inc. logoNASDAQ:VTGN$0.1683-1.41%
Phase Distribution
11 lead-sponsored trials·3 active·4 completed
Phase 12
Phase 24
Phase 35
(1 more as collaborator)
Status Overview
Recruiting1
Active, not recruiting2
Completed4
Stopped2
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

    PH94B Nasal Spray, Placebo Nasal Spray

    Social Anxiety Disorder

    Enrollment
    224
    Start
    May 2021
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT04754802
  • Phase 3
    Terminated

    PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2

    PH94B Nasal Spray, Placebo Nasal Spray

    Social Anxiety Disorder

    Enrollment
    228
    Start
    Aug 2021
    Primary Completion
    Aug 2022
    Completion
    Aug 2022
    NCT05011396
  • Phase 3
    Terminated

    Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD)

    PH94B

    Social Anxiety Disorder

    Enrollment
    481
    Start
    Oct 2021
    Primary Completion
    Sep 2022
    Completion
    Sep 2022
    NCT05030350
  • Phase 3
    Active, not recruiting

    Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)

    Fasedienol Nasal Spray, Placebo Nasal Spray

    Social Anxiety Disorder

    Enrollment
    238
    Start
    Mar 2024
    Primary Completion
    Oct 2025
    Completion
    Oct 2026est.
    NCT06358651
  • Phase 3
    Active, not recruiting

    Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

    Fasedienol Nasal Spray, Placebo Nasal Spray

    Social Anxiety Disorder (SAD)

    Enrollment
    238
    Start
    Sep 2024
    Primary Completion
    Apr 2026
    Completion
    Apr 2027est.
    NCT06615557
  • Phase 2
    Completed

    AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression

    AV-101, Placebo

    Major Depressive Disorder

    Enrollment
    180
    Start
    Mar 2018
    Primary Completion
    Oct 2019
    Completion
    Oct 2019
    NCT03078322
  • Phase 2
    Unknown status

    AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

    AV-101, Placebo

    Parkinson Disease, Dyskinesia, Medication-Induced +1

    Enrollment
    20
    Start
    Aug 2022est.
    Primary Completion
    Dec 2023est.
    Completion
    Apr 2024est.
    NCT04147949
  • Phase 2
    Completed

    PH94B in the Treatment of Adjustment Disorder With Anxiety

    PH94B, Placebo

    Adjustment Disorder With Anxious Mood

    Enrollment
    41
    Start
    Oct 2021
    Primary Completion
    Dec 2022
    Completion
    Dec 2022
    NCT04404192
  • Phase 2
    Recruiting

    A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

    Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray

    Social Anxiety Disorder

    Enrollment
    60
    Start
    Jan 2025
    Primary Completion
    Apr 2026est.
    Completion
    Dec 2026est.
    NCT06809179
  • Phase 1
    Completed

    Safety, Tolerability and Pharmacokinetics of Multiple Doses of AV-101 in Healthy Volunteers

    AV-101, Placebo

    Neuropathic Pain

    Enrollment
    50
    Start
    Dec 2011
    Primary Completion
    Sep 2012
    Completion
    Sep 2012
    NCT01483846
  • Phase 1
    Unknown status

    AV-101 Alone and in Combination With Probenecid in Healthy Subjects

    AV-101, Probenecid

    Drug Drug Interaction

    Enrollment
    24
    Start
    Dec 2021
    Primary Completion
    Sep 2022est.
    Completion
    Nov 2022est.
    NCT05280054
Search ClinicalTrials.gov for “Vistagen Therapeutics”